Dopamine

Dopamine
Ben Mills · Public domain · source
Name	Dopamine
IUPAC	4-(2-aminoethyl)benzene-1,2-diol
Formula	C8H11NO2
Molar mass	153.18 g·mol−1

Dopamine is a catecholamine neurotransmitter and neuromodulator synthesized in several ventral tegmental area- and substantia nigra-containing pathways and implicated in motor control, reward, and neuroendocrine regulation. It was first identified in vertebrate brain tissue during mid-20th century biochemical work and later linked to disorders treated at institutions like Massachusetts General Hospital and Mayo Clinic. Dopamine signaling is studied across laboratories at universities such as Harvard University, University of Oxford, and Stanford University and appears in research contexts ranging from Parkinson's disease clinics to cognitive studies at the Max Planck Society.

Chemistry and biosynthesis

Dopamine is an organic compound with a catechol ring and an ethylamine side chain; chemists at places like University of Chicago and ETH Zurich analyze its structure using methods developed by Linus Pauling and Dorothy Hodgkin. Biosynthesis begins with the amino acid tyrosine, converted by tyrosine hydroxylase to L-DOPA and then by aromatic L-amino acid decarboxylase to dopamine, processes characterized in pathways studied at Johns Hopkins University and Columbia University. Enzymatic cofactors such as tetrahydrobiopterin, identified in biochemical work at Karolinska Institutet, and transporters like the vesicular monoamine transporter studied at Scripps Research Institute are essential for synthesis and storage. Catabolic enzymes monoamine oxidase, investigated in pharmacology at GlaxoSmithKline and Eli Lilly and Company, and catechol-O-methyltransferase contribute to degradation, producing metabolites measured in clinical labs at Cleveland Clinic and Imperial College London.

Physiology and neural functions

Dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area project to the striatum, prefrontal cortex, and nucleus accumbens, forming circuits examined in animal work at Cold Spring Harbor Laboratory and human imaging at National Institutes of Health. Signaling occurs through G protein-coupled receptors classified as D1-like and D2-like families, a framework developed in receptor pharmacology at Yale University and University College London. Dopamine modulates synaptic plasticity studied in laboratories at Salk Institute and influences motor programs coordinated by the basal ganglia, subjects of research at University of California, San Francisco. It also regulates prolactin secretion via hypothalamic pathways involving the pituitary gland, topics of endocrine research at University of Pennsylvania and Mount Sinai Health System.

Role in behavior and cognition

Dopamine underlies reinforcement learning mechanisms characterized in computational neuroscience at California Institute of Technology and Massachusetts Institute of Technology and contributes to motivation studied in behavioral work at Princeton University and University of Cambridge. Its involvement in attention and working memory implicates prefrontal circuits explored by teams at Duke University and University of Michigan. Reward prediction error signalling, a concept refined by researchers like those affiliated with University College London and Columbia University, links dopamine to decision-making analyzed in studies at New York University and University of Toronto. Social behaviors, risk-taking, and addiction-related processes are topics in clinical and translational research at Yale School of Medicine and University of California, Los Angeles.

Clinical significance and disorders

Degeneration of nigrostriatal dopamine neurons produces motor symptoms treated at centers such as Johns Hopkins Hospital and National Hospital for Neurology and Neurosurgery; this association underpins the clinical syndrome managed across United Kingdom National Health Service neurology departments and international Parkinson's disease consortia. Hyperdopaminergic states and receptor dysregulation are implicated in psychotic disorders treated in psychiatric units at Beth Israel Deaconess Medical Center and Kings College London. Dopaminergic dysfunction also contributes to attention-deficit/hyperactivity disorder clinics in systems like Kaiser Permanente and impulse-control disorders studied at University of Pittsburgh Medical Center. Endocrine and metabolic links are investigated in centers such as Mayo Clinic and University of California, San Diego.

Pharmacology and therapeutics

Drugs targeting dopaminergic systems include agonists and antagonists developed and marketed by companies like Bristol-Myers Squibb and Roche. Levodopa remains the mainstay for Parkinsonian motor symptoms in treatment centers such as Royal Free Hospital and Karolinska University Hospital, while antipsychotics blocking D2 receptors are used in protocols at Maudsley Hospital and Massachusetts General Hospital. Dopamine transporter inhibitors and releasers figure in addiction medicine programs at Hazelden Betty Ford Foundation and substance-use research at Johns Hopkins Bloomberg School of Public Health. Novel modulators and gene therapies are being trialed in collaborative networks including European Medicines Agency-sponsored studies and National Institute of Mental Health consortia.

Measurement and research methods

Dopamine levels and receptor occupancy are assessed using techniques like positron emission tomography developed at Brookhaven National Laboratory and functional MRI protocols refined at Aarhus University Hospital and UCLA Medical Center. Microdialysis and electrochemical detection in animal models are performed in facilities at University of British Columbia and Monash University. Genetic and proteomic approaches from groups at Broad Institute and Wellcome Trust Sanger Institute elucidate regulatory machinery, while optogenetic manipulation pioneered at University of North Carolina at Chapel Hill and Howard Hughes Medical Institute enables causal tests. Clinical trials and longitudinal cohorts, coordinated through organizations such as World Health Organization and European Union research programs, continue to advance translational understanding.

Category:Neurotransmitters